Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00035061 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Trial of ALIMTA (Pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00035061: Completed Phase 2 study, sponsored by Eli Lilly and Company.
NCT00035061 is a Phase 2 study that has completed, run by Eli Lilly and Company. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00035061, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
Patients with bladder cancer will be participating in this study for the treatment of abnormal cells in the bladder that have returned after initial treatment OR have moved to a new site in the body.
Interventions
- DRUG pemetrexed
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 2 |
What the finished NCT00035061 record still lists
NCT00035061 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which pemetrexed is the first listed.
NCT00035061 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00035061 about?
NCT00035061 is a clinical study titled "A Phase 2 Trial of ALIMTA (Pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium". Patients with bladder cancer will be participating in this study for the treatment of abnormal cells in the bladder that have returned after initial treatment OR have moved to a new site in the body.
What is the current status of trial NCT00035061?
This trial is currently completed. It is a Phase 2 study.
What interventions are being tested in trial NCT00035061?
The interventions under investigation include: pemetrexed (DRUG).
Who is sponsoring clinical trial NCT00035061?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.